US4150149A
(en)
|
1976-11-29 |
1979-04-17 |
Professional Staff Association Of The Los Angeles County Harbor General Hospital |
Method and means for the early detection and diagnosis of certain types of cancers
|
US4444744A
(en)
|
1980-03-03 |
1984-04-24 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibodies to cell surface antigens
|
US4361544A
(en)
|
1980-03-03 |
1982-11-30 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
JPH07509444A
(ja)
|
1991-11-26 |
1995-10-19 |
アルカーメス・インコーポレーテツド |
トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
CA2145985C
(en)
|
1992-10-28 |
2003-09-16 |
Napoleone Ferrara |
Vascular endothelial cell growth factor antagonists
|
US5747654A
(en)
|
1993-06-14 |
1998-05-05 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant disulfide-stabilized polypeptide fragments having binding specificity
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
US5814464A
(en)
|
1994-10-07 |
1998-09-29 |
Regeneron Pharma |
Nucleic acids encoding TIE-2 ligand-2
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
GB9504344D0
(en)
|
1995-03-03 |
1995-04-19 |
Unilever Plc |
Antibody fragment production
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
WO1997014719A1
(en)
|
1995-10-16 |
1997-04-24 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
JP2000508892A
(ja)
|
1996-04-04 |
2000-07-18 |
ユニリーバー・ナームローゼ・ベンノートシャープ |
多価および多特異的抗原結合タンパク
|
AU4333397A
(en)
|
1996-09-05 |
1998-03-26 |
Adrenaline Research, Inc. |
High power spark plug wire
|
EP0973804B1
(en)
|
1997-04-07 |
2006-12-27 |
Genentech, Inc. |
Anti-vegf antibodies
|
EP3260468A1
(en)
|
1997-04-07 |
2017-12-27 |
Genentech, Inc. |
Anti-vegf antibodies
|
WO1998048032A2
(en)
|
1997-04-21 |
1998-10-29 |
Donlar Corporation |
POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
|
DE69830901T2
(de)
|
1997-05-02 |
2006-05-24 |
Genentech Inc., San Francisco |
ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
DE69830315T2
(de)
|
1997-06-24 |
2006-02-02 |
Genentech Inc., San Francisco |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
ATE419009T1
(de)
|
1997-10-31 |
2009-01-15 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
EP1049787B1
(en)
|
1998-01-23 |
2004-11-24 |
Vlaams Interuniversitair Instituut voor Biotechnologie |
Multipurpose antibody derivatives
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
AU3657899A
(en)
|
1998-04-20 |
1999-11-08 |
James E. Bailey |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
ATE460946T1
(de)
|
1998-06-22 |
2010-04-15 |
Immunomedics Inc |
Gebrauch von bispezifischen antikörpern in diagnose und therapie
|
US6312689B1
(en)
|
1998-07-23 |
2001-11-06 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR2 antibodies and methods of use therefor
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
AU1687500A
(en)
|
1998-12-16 |
2000-07-03 |
Kyowa Hakko Kogyo Co. Ltd. |
Antihuman vegf monoclonal antibody
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
CN1232039A
(zh)
|
1999-04-02 |
1999-10-20 |
中国人民解放军海军总医院 |
一种基因工程双特异抗体及其应用
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
AU782626B2
(en)
|
1999-10-04 |
2005-08-18 |
Medicago Inc. |
Method for regulating transcription of foreign genes
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PRODUCING A POLYPEPTIDE
|
US7449443B2
(en)
|
2000-03-23 |
2008-11-11 |
California Institute Of Technology |
Method for stabilization of proteins using non-natural amino acids
|
JP2004500108A
(ja)
|
2000-03-24 |
2004-01-08 |
マイクロメット アーゲー |
Nkg2dレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド
|
ES2528794T3
(es)
|
2000-04-11 |
2015-02-12 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
DE10021678A1
(de)
|
2000-05-05 |
2002-04-18 |
Stefan Duebel |
Antikörperkonstrukte mit variablen Regionen
|
EP1299419A2
(en)
|
2000-05-24 |
2003-04-09 |
Imclone Systems, Inc. |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
CA2424602C
(en)
|
2000-10-06 |
2012-09-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-producing cell
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
AU1091802A
(en)
|
2000-10-20 |
2002-04-29 |
Chugai Pharmaceutical Co Ltd |
Degraded agonist antibody
|
RU2430927C2
(ru)
|
2000-10-20 |
2011-10-10 |
Тугаи Сейяку Кабусики Кайся |
Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
|
WO2002096948A2
(en)
|
2001-01-29 |
2002-12-05 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
US20030099974A1
(en)
|
2001-07-18 |
2003-05-29 |
Millennium Pharmaceuticals, Inc. |
Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
|
NZ592087A
(en)
|
2001-08-03 |
2012-11-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
AU2002359244A1
(en)
|
2001-09-05 |
2003-04-28 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of |
Imaging the activity of extracellular proteases in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
|
ES2276735T3
(es)
|
2001-09-14 |
2007-07-01 |
Affimed Therapeutics Ag |
Anticuerpos fv multimericos de cadena sencilla en tandem.
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
DE60237704D1
(de)
|
2001-10-16 |
2010-10-28 |
Government Of The Us Secretary |
Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
|
US7053202B2
(en)
|
2001-10-19 |
2006-05-30 |
Millennium Pharmaceuticals, Inc. |
Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
AU2003248370A1
(en)
|
2002-02-27 |
2003-09-09 |
California Institute Of Technology |
Computational method for designing enzymes for incorporation of amino acid analogs into proteins
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
CA2484182A1
(en)
|
2002-04-29 |
2003-11-13 |
Genpat77 Pharmacogenetics Ag |
Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
|
US7081443B2
(en)
|
2002-05-21 |
2006-07-25 |
Korea Advanced Institutes Of Science And Technology (Kaist) |
Chimeric comp-ang1 molecule
|
SE0201863D0
(en)
|
2002-06-18 |
2002-06-18 |
Cepep Ab |
Cell penetrating peptides
|
PT1517921E
(pt)
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
Ligandos duplamente especificos com semi-vida no soro aumentada
|
US7140727B2
(en)
|
2002-07-10 |
2006-11-28 |
Isl Technologies, Llc |
Eyeglass frame assembly
|
EP1549345A1
(en)
|
2002-10-10 |
2005-07-06 |
MERCK PATENT GmbH |
Bispecific anti-erb-b antibodies and their use in tumor therapy
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
ES2574993T3
(es)
|
2003-01-22 |
2016-06-23 |
Roche Glycart Ag |
Construcciones de fusión y uso de las mismas para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
|
BRPI0407446A
(pt)
|
2003-02-13 |
2006-01-31 |
Pharmacia Corp |
Anticorpos para c-met para o tratamento de cânceres
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
MXPA05012723A
(es)
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
US7700097B2
(en)
|
2003-06-27 |
2010-04-20 |
Biogen Idec Ma Inc. |
Purification and preferential synthesis of binding molecules
|
JP5026072B2
(ja)
|
2003-07-01 |
2012-09-12 |
イミューノメディクス、インコーポレイテッド |
二重特異性抗体の多価キャリヤー
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
CA2534077A1
(en)
|
2003-07-29 |
2005-02-10 |
Morphotek Inc. |
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
AU2004273791A1
(en)
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
US20050064509A1
(en)
|
2003-09-23 |
2005-03-24 |
The Regents Of The University Of California |
Use of templated self assembly to create novel multifunctional species
|
CN1326881C
(zh)
|
2003-09-29 |
2007-07-18 |
中国人民解放军军事医学科学院基础医学研究所 |
一种三价双特异性抗体,其制备方法及用途
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
SG143252A1
(en)
|
2003-10-09 |
2008-06-27 |
Ambrx Inc |
Polymer derivatives
|
EA036531B1
(ru)
|
2003-11-05 |
2020-11-19 |
Роше Гликарт Аг |
Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
|
WO2005051976A2
(en)
|
2003-11-20 |
2005-06-09 |
Ansata Therapeutics, Inc. |
Protein and peptide ligation processes and one-step purification processes
|
JP4833850B2
(ja)
|
2003-11-21 |
2011-12-07 |
ユセベ ファルマ ソシエテ アノニム |
Il−17活性阻害による多発性硬化症を治療するための方法
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
AU2005211362B2
(en)
|
2004-02-02 |
2008-03-13 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
WO2005075514A2
(en)
|
2004-03-10 |
2005-08-18 |
Lonza Ltd. |
Method for producing antibodies
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
CA2577133A1
(en)
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
EP1791565B1
(en)
|
2004-09-23 |
2016-04-20 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
AU2005319382B2
(en)
|
2004-12-21 |
2011-04-07 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
NZ556286A
(en)
|
2005-02-07 |
2010-11-26 |
Glycart Biotechnology Ag |
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
|
WO2006091209A2
(en)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
EP1863844A1
(en)
|
2005-02-28 |
2007-12-12 |
Centocor, Inc. |
Heterodimeric protein binding compositions
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
TW200722518A
(en)
|
2005-03-31 |
2007-06-16 |
Chugai Pharmaceutical Co Ltd |
Sc(fv)2 structural isomers
|
TW200720289A
(en)
|
2005-04-01 |
2007-06-01 |
Hoffmann La Roche |
Antibodies against CCR5 and uses thereof
|
CA2605024C
(en)
|
2005-04-15 |
2018-05-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US20090215639A1
(en)
|
2005-04-26 |
2009-08-27 |
Bioren, Inc. |
Method of Producing Human IgG Antibodies with Enhanced Effector Functions
|
CA2606102C
(en)
|
2005-04-26 |
2014-09-30 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
EP1925319B1
(en)
|
2005-06-10 |
2018-03-07 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(fv)2
|
JP5085322B2
(ja)
|
2005-06-10 |
2012-11-28 |
中外製薬株式会社 |
sc(Fv)2を含有する医薬組成物
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
RU2515108C2
(ru)
|
2005-08-19 |
2014-05-10 |
Эббви Инк |
Иммуноглобулин с двойными вариабельными доменами и его применения
|
US20070071745A1
(en)
|
2005-08-26 |
2007-03-29 |
Pablo Umana |
Modified antigen binding molecules with altered cell signaling activity
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
US7666622B2
(en)
|
2005-10-19 |
2010-02-23 |
Regeneron Pharmaceuticals, Inc. |
Monomeric self-associating fusion polypeptides and therapeutic uses thereof
|
TW200732350A
(en)
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
FR2894959B1
(fr)
|
2005-12-15 |
2008-02-29 |
Galderma Res & Dev |
Derives biphenyliques agonistes selectifs du recepteur rar-gamma
|
WO2007068895A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
GB0601513D0
(en)
|
2006-01-25 |
2006-03-08 |
Univ Erasmus Medical Ct |
Binding molecules 3
|
US8102403B1
(en)
|
2006-01-25 |
2012-01-24 |
Pixar |
Techniques for interior coordinates
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
JP2009526857A
(ja)
|
2006-02-15 |
2009-07-23 |
イムクローン・リミテッド・ライアビリティ・カンパニー |
機能性抗体
|
CA2646508A1
(en)
|
2006-03-17 |
2007-09-27 |
Biogen Idec Ma Inc. |
Stabilized polypeptide compositions
|
WO2007108013A2
(en)
|
2006-03-22 |
2007-09-27 |
National Institute Of Immunology |
Novel bioconjugates as therapeutic agent and synthesis thereof
|
AU2007229698B9
(en)
|
2006-03-24 |
2012-11-08 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
AU2007261782A1
(en)
|
2006-06-06 |
2007-12-27 |
Oleg Iliich Epshtein |
Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
|
NZ574093A
(en)
|
2006-06-12 |
2011-03-31 |
Symphogen As |
Pan-cell surface receptor- specific therapeutics
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
二重特異性抗体の生産
|
WO2008005828A2
(en)
|
2006-06-30 |
2008-01-10 |
Novo Nordisk A/S |
PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS COMPRISING ANTIBODY MOLECULES SPECIFIC TO LAMININ-5 α3 CHAIN DOMAINS G1G2 AND USE THEREOF
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
US8497246B2
(en)
|
2006-08-18 |
2013-07-30 |
Armagen Technologies, Inc. |
Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
CN101205255A
(zh)
|
2006-12-14 |
2008-06-25 |
上海中信国健药业有限公司 |
抗cd20四价抗体、其制备方法和应用
|
SG10201503407WA
(en)
|
2006-12-19 |
2015-06-29 |
Genentech Inc |
Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
PL2716301T3
(pl)
|
2007-02-16 |
2017-10-31 |
Merrimack Pharmaceuticals Inc |
Przeciwciała przeciw ERBB3 i ich zastosowania
|
US10259860B2
(en)
|
2007-02-27 |
2019-04-16 |
Aprogen Inc. |
Fusion proteins binding to VEGF and angiopoietin
|
JP2010535032A
(ja)
|
2007-07-31 |
2010-11-18 |
メディミューン,エルエルシー |
多重特異性エピトープ結合性タンパク質およびその用途
|
EP2201051A1
(en)
|
2007-08-15 |
2010-06-30 |
Isp Investments Inc. |
Polyvinylamide polymers containing polymerizable functionalities
|
WO2009021754A2
(en)
|
2007-08-15 |
2009-02-19 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
DE102007038753A1
(de)
|
2007-08-16 |
2009-02-19 |
Giesecke & Devrient Gmbh |
Vorrichtung und Verfahren für die Kalibrierung eines Sensorsystems
|
KR20100052545A
(ko)
|
2007-08-28 |
2010-05-19 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Igf―1r의 다중 에피토프에 결합하는 조성물
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
*
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
*
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
JP2009181819A
(ja)
|
2008-01-31 |
2009-08-13 |
Hitachi High-Technologies Corp |
荷電粒子線装置
|
JP4438875B2
(ja)
|
2008-02-27 |
2010-03-24 |
三菱自動車工業株式会社 |
車両の貯蔵燃料量推定装置
|
ES2368700T3
(es)
|
2008-04-11 |
2011-11-21 |
Emergent Product Development Seattle, Llc |
Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
|
KR20110047255A
(ko)
|
2008-09-26 |
2011-05-06 |
로슈 글리카트 아게 |
이중특이적 항-egfr/항-igf-1r 항체
|
US8268314B2
(en)
*
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
KR20190025057A
(ko)
|
2008-10-14 |
2019-03-08 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 그의 용도
|
BRPI0922807A2
(pt)
|
2008-12-04 |
2015-12-22 |
Abbott Lab |
imonuglobulinas de domínio variável duplo e usos dos mesmos
|
EP2389392A1
(en)
|
2009-01-26 |
2011-11-30 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
WO2010087994A2
(en)
|
2009-01-30 |
2010-08-05 |
Whitehead Institute For Biomedical Research |
Methods for ligation and uses thereof
|
ES2572728T3
(es)
|
2009-03-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HER biespecíficos
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
EP2417156B1
(en)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalent, bispecific antibodies
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
DE102009016373A1
(de)
|
2009-04-07 |
2010-10-21 |
V. KRÜTTEN MEDIZINISCHE EINMALGERÄTE GmbH |
Verbindungsstück für den Sondenschlauch einer enteralen Ernährungssonde und Anordnung aus einer enteralen Ernährungssonde und einem enteralen Überleitsystem
|
MX2011010169A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-1/anti-c-met.
|
CN102459346B
(zh)
*
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
WO2010136172A1
(en)
|
2009-05-27 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
US9050375B2
(en)
|
2009-07-06 |
2015-06-09 |
Hoffmann-La Roche, Inc. |
Bi-specific digoxigenin binding antibodies
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
RU2015153109A
(ru)
|
2009-09-16 |
2019-01-15 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применения
|
CN102574921B
(zh)
|
2009-09-29 |
2016-05-04 |
罗切格利卡特公司 |
双特异性死亡受体激动型抗体
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
EP3095871B1
(en)
|
2010-02-08 |
2019-04-10 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
AR080794A1
(es)
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
WO2011118739A1
(ja)
|
2010-03-26 |
2011-09-29 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
MX338953B
(es)
|
2010-08-16 |
2016-05-06 |
Novimmune Sa |
Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
|
RU2013110876A
(ru)
|
2010-08-24 |
2014-09-27 |
Рош Гликарт Аг |
Активируемые биспецифические антитела
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
AR084053A1
(es)
|
2010-11-30 |
2013-04-17 |
Chugai Pharmaceutical Co Ltd |
Agente terapeutico que induce citotoxicidad
|
SI2646470T1
(sl)
|
2010-11-30 |
2017-05-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
|
ES2549638T3
(es)
|
2011-02-28 |
2015-10-30 |
F. Hoffmann-La Roche Ag |
Proteínas de unión a antígeno
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
EA028804B1
(ru)
|
2011-03-25 |
2018-01-31 |
Гленмарк Фармасьютикалс С.А. |
Гетеродимерные иммуноглобулины
|
JP2014514313A
(ja)
|
2011-04-20 |
2014-06-19 |
ロシュ グリクアート アクチェンゲゼルシャフト |
血液脳関門のpH依存性通過のための方法及び構築物
|
CN103764665A
(zh)
|
2011-06-28 |
2014-04-30 |
怀特黑德生物医学研究所 |
使用分选酶安装用于蛋白质连接的点击化学柄
|
BR112013032630B1
(pt)
|
2011-06-30 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídeo heterodimerizado compreendendo região fc de igg
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
SI2748202T1
(sl)
|
2011-08-23 |
2018-10-30 |
Roche Glycart Ag |
Bispecifične molekule, ki se vežejo na antigen
|
US9309306B2
(en)
|
2011-08-23 |
2016-04-12 |
Roche Glycart Ag |
Anti-MCSP antibodies
|
RU2617970C2
(ru)
*
|
2011-08-23 |
2017-04-28 |
Рош Гликарт Аг |
Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения
|
KR101870555B1
(ko)
*
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
CN103748114B
(zh)
|
2011-08-23 |
2017-07-21 |
罗切格利卡特公司 |
T细胞活化性双特异性抗原结合分子
|
CN109134658B
(zh)
|
2011-10-31 |
2022-10-14 |
中外制药株式会社 |
控制了重链与轻链的缔合的抗原结合分子
|
JP6441079B2
(ja)
|
2011-12-19 |
2018-12-19 |
シンイミューン ゲーエムベーハー |
二重特異性抗体分子
|
CA2859667C
(en)
|
2011-12-20 |
2022-05-24 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
CA2854243A1
(en)
|
2011-12-21 |
2013-06-27 |
Simone HOEGE |
Rapid method for cloning and expression of cognate antibody variable region gene segments
|
SG11201406238UA
(en)
|
2012-04-05 |
2014-10-30 |
Hoffmann La Roche |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
MX360109B
(es)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Metodos y medios para la produccion de moleculas de tipo ig.
|
MX2014014162A
(es)
|
2012-05-24 |
2015-02-04 |
Hoffmann La Roche |
Anticuerpos multiespecificos.
|
RU2015100656A
(ru)
|
2012-06-27 |
2016-08-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
|
BR112014029888A2
(pt)
|
2012-06-27 |
2020-05-12 |
Hoffmann La Roche |
Métodos de produção de um anticorpo, de determinação de uma combinação de sítios de ligação e de tratamento de um indivíduo com câncer, formulação farmacêutica, anticorpo e uso de um anticorpo
|
JP2015528003A
(ja)
|
2012-07-13 |
2015-09-24 |
ザイムワークス,インコーポレイテッド |
抗cd3構築物を含む二重特異性の非対称ヘテロ二量体
|
WO2014041072A1
(en)
|
2012-09-14 |
2014-03-20 |
F. Hoffmann-La Roche Ag |
Method for the production and selection of molecules comprising at least two different entities and uses thereof
|
AU2013322710A1
(en)
|
2012-09-25 |
2015-04-16 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
WO2014056783A1
(en)
*
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
WO2014082179A1
(en)
|
2012-11-28 |
2014-06-05 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
DK2940135T5
(da)
|
2012-12-27 |
2021-09-20 |
Chugai Pharmaceutical Co Ltd |
Heterodimeriseret polypeptid
|
US9605084B2
(en)
*
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US20160009824A1
(en)
|
2013-03-15 |
2016-01-14 |
Merck Patent Gmbh |
Tetravalent bispecific antibodies
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
AU2014332458B2
(en)
*
|
2013-09-05 |
2020-03-12 |
Igm Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
|
JP6510532B2
(ja)
*
|
2013-12-20 |
2019-05-08 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性her2抗体及び使用方法
|
EP3092251B1
(en)
|
2014-01-06 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Monovalent blood brain barrier shuttle modules
|
WO2015107026A1
(en)
*
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
EP3842455A1
(en)
*
|
2014-01-15 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with improved protein a-binding
|
JP6873701B2
(ja)
*
|
2014-01-15 |
2021-05-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
FcRn結合特性が改変されているFc領域変異体
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
CN106573986A
(zh)
|
2014-07-29 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
PE20170263A1
(es)
|
2014-08-04 |
2017-03-30 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
MX2017004526A
(es)
|
2014-10-08 |
2017-06-07 |
Hoffmann La Roche |
Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
|
ES2850325T3
(es)
|
2014-10-09 |
2021-08-27 |
Engmab Sarl |
Anticuerpos biespecíficos contra CD3epsilon y ROR1
|
PL3221357T3
(pl)
*
|
2014-11-20 |
2020-11-02 |
F. Hoffmann-La Roche Ag |
Wspólne łańcuchy lekkie i sposoby zastosowania
|
MX2017006571A
(es)
*
|
2014-11-20 |
2017-09-29 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas activadoras de celulas t.
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
BR112018002570A2
(pt)
*
|
2015-10-02 |
2018-10-16 |
Hoffmann La Roche |
molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
|
JP6937746B2
(ja)
|
2015-10-02 |
2021-09-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗cd19×cd3t細胞活性化抗原結合分子
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
WO2017055318A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cd33xcd3 bispecific t cell activating antigen binding molecules
|
KR102146319B1
(ko)
|
2015-10-02 |
2020-08-25 |
에프. 호프만-라 로슈 아게 |
Pd1 및 tim3에 특이적인 이중특이성 항체
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
WO2017055388A2
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
CN108290958B
(zh)
|
2015-10-02 |
2021-12-28 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
AU2016334623A1
(en)
*
|
2015-10-07 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory TNF receptor
|